{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:13:46Z","timestamp":1760908426665,"version":"build-2065373602"},"reference-count":153,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2007,12,1]],"date-time":"2007-12-01T00:00:00Z","timestamp":1196467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,12,1]],"date-time":"2007-12-01T00:00:00Z","timestamp":1196467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2007,12]]},"DOI":"10.1016\/j.hoc.2007.08.004","type":"journal-article","created":{"date-parts":[[2007,12,6]],"date-time":"2007-12-06T15:08:55Z","timestamp":1196953735000},"page":"985-1006","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Molecular Pathogenesis of Multiple Myeloma"],"prefix":"10.1016","volume":"21","author":[{"given":"Giovanni","family":"Tonon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.hoc.2007.08.004_bib1","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ccr.2004.10.020","article-title":"Focus on multiple myeloma","volume":"6","author":"Mitsiades","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.hoc.2007.08.004_bib2","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1034\/j.1600-065X.2003.00056.x","article-title":"Monoclonal gammopathies of undetermined significance: a review","volume":"194","author":"Kyle","year":"2003","journal-title":"Immunol Rev"},{"issue":"18","key":"10.1016\/j.hoc.2007.08.004_bib3","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1056\/NEJMra041875","article-title":"Multiple myeloma","volume":"351","author":"Kyle","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hoc.2007.08.004_bib4","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1182\/asheducation-2002.1.214","article-title":"Multiple myeloma","author":"Anderson","year":"2002","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"3","key":"10.1016\/j.hoc.2007.08.004_bib5","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nrc746","article-title":"Multiple myeloma: evolving genetic events and host interactions","volume":"2","author":"Kuehl","year":"2002","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"10.1016\/j.hoc.2007.08.004_bib6","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1182\/blood-2005-02-0691","article-title":"Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma","volume":"106","author":"Richardson","year":"2005","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2007.08.004_bib7","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.beha.2005.01.010","article-title":"Novel biological therapies for the treatment of multiple myeloma","volume":"18","author":"Richardson","year":"2005","journal-title":"Best Pract Res Clin Haematol"},{"issue":"1","key":"10.1016\/j.hoc.2007.08.004_bib8","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1182\/blood-2003-04-1045","article-title":"Treatment of multiple myeloma","volume":"103","author":"Barlogie","year":"2004","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2007.08.004_bib9","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2005-01-0034","article-title":"Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma","volume":"106","author":"Bergsagel","year":"2005","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2007.08.004_bib10","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ccr.2006.03.019","article-title":"High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients","volume":"9","author":"Carrasco","year":"2006","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.hoc.2007.08.004_bib11","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","article-title":"The molecular classification of multiple myeloma","volume":"108","author":"Zhan","year":"2006","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2007.08.004_bib12","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1038\/sj.leu.2401041","article-title":"Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases","volume":"12","author":"Smadja","year":"1998","journal-title":"Leukemia"},{"issue":"15","key":"10.1016\/j.hoc.2007.08.004_bib13","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMra023001","article-title":"Acute lymphoblastic leukemia","volume":"350","author":"Pui","year":"2004","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.hoc.2007.08.004_bib14","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0165-4608(94)00284-I","article-title":"Cytogenetic findings in 200 patients with multiple myeloma","volume":"82","author":"Sawyer","year":"1995","journal-title":"Cancer Genet Cytogenet"},{"issue":"9","key":"10.1016\/j.hoc.2007.08.004_bib15","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1182\/blood.V85.9.2490.bloodjournal8592490","article-title":"Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patients at diagnosis","volume":"85","author":"Lai","year":"1995","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.hoc.2007.08.004_bib16","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1182\/blood.V98.7.2229","article-title":"Hypodiploidy is a major prognostic factor in multiple myeloma","volume":"98","author":"Smadja","year":"2001","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.hoc.2007.08.004_bib17","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1182\/blood-2003-02-0493","article-title":"The recurrent IgH translocations are highly\u00a0associated with nonhyperdiploid variant multiple myeloma","volume":"102","author":"Fonseca","year":"2003","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2007.08.004_bib18","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1182\/blood-2005-02-0761","article-title":"A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS","volume":"106","author":"Chng","year":"2005","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2007.08.004_bib19","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.leukres.2005.07.004","article-title":"Ploidy status rarely changes in myeloma patients at disease progression","volume":"30","author":"Chng","year":"2006","journal-title":"Leuk Res"},{"issue":"12","key":"10.1016\/j.hoc.2007.08.004_bib20","doi-asserted-by":"crossref","first-page":"4164","DOI":"10.1073\/pnas.0308531101","article-title":"Metagenes and molecular pattern discovery using matrix factorization","volume":"101","author":"Brunet","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"40","key":"10.1016\/j.hoc.2007.08.004_bib21","doi-asserted-by":"crossref","first-page":"5611","DOI":"10.1038\/sj.onc.1204641","article-title":"Chromosome translocations in multiple myeloma","volume":"20","author":"Bergsagel","year":"2001","journal-title":"Oncogene"},{"issue":"24","key":"10.1016\/j.hoc.2007.08.004_bib22","doi-asserted-by":"crossref","first-page":"13931","DOI":"10.1073\/pnas.93.24.13931","article-title":"Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma","volume":"93","author":"Bergsagel","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.hoc.2007.08.004_bib23","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/sj.leu.2402797","article-title":"Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma","volume":"17","author":"Debes-Marun","year":"2003","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.hoc.2007.08.004_bib24","first-page":"1401","article-title":"Gene rearrangement and overexpression of PRAD1 in\u00a0lymphoid malignancy with t(11;14)(q13;q32) translocation","volume":"7","author":"Seto","year":"1992","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.hoc.2007.08.004_bib25","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1182\/blood.V88.2.674.bloodjournal882674","article-title":"Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines","volume":"88","author":"Chesi","year":"1996","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2007.08.004_bib26","first-page":"377","article-title":"Messenger RNA levels of five genes located at chromosome 11q13 in B-cell tumors with chromosome translocation t(11;14)(q13;q32)","volume":"54","author":"Akiyama","year":"1994","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.hoc.2007.08.004_bib27","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1159\/000204010","article-title":"Overexpression of the PRAD1 oncogene in a patient with multiple myeloma and t(11;14)(q13;q32)","volume":"94","author":"Kobayashi","year":"1995","journal-title":"Acta Haematol"},{"issue":"1","key":"10.1016\/j.hoc.2007.08.004_bib28","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1097-2765(00)80180-X","article-title":"Insertion of excised IgH switch sequences causes overexpression of cyclin D1 in a myeloma tumor cell","volume":"3","author":"Gabrea","year":"1999","journal-title":"Mol Cell"},{"issue":"1","key":"10.1016\/j.hoc.2007.08.004_bib29","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1182\/blood.V98.1.217","article-title":"Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma","volume":"98","author":"Shaughnessy","year":"2001","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2007.08.004_bib30","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/ng0797-260","article-title":"Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3","volume":"16","author":"Chesi","year":"1997","journal-title":"Nat Genet"},{"issue":"10","key":"10.1016\/j.hoc.2007.08.004_bib31","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.1182\/blood.V90.10.4062","article-title":"A novel chromosomal translocation t(4; 14)(p16.3; q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene","volume":"90","author":"Richelda","year":"1997","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2007.08.004_bib32","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1182\/blood.V92.9.3025","article-title":"The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH\/MMSET hybrid transcripts","volume":"92","author":"Chesi","year":"1998","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2007.08.004_bib33","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1182\/blood.V97.3.729","article-title":"Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma","volume":"97","author":"Chesi","year":"2001","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2007.08.004_bib34","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1046\/j.1365-2141.2001.02957.x","article-title":"Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14)","volume":"114","author":"Intini","year":"2001","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.hoc.2007.08.004_bib35","doi-asserted-by":"crossref","first-page":"4457","DOI":"10.1182\/blood.V91.12.4457.412k48_4457_4463","article-title":"Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma","volume":"91","author":"Chesi","year":"1998","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2007.08.004_bib36","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/j.1349-7006.2001.tb01142.x","article-title":"Ectopic expression of MAFB gene in human myeloma cells carrying (14;20)(q32;q11) chromosomal translocations","volume":"92","author":"Hanamura","year":"2001","journal-title":"Jpn J Cancer Res"},{"issue":"3","key":"10.1016\/j.hoc.2007.08.004_bib37","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/gcc.10275","article-title":"Further cytogenetic characterization of multiple myeloma confirms that 14q32 translocations are a very rare event in hyperdiploid cases","volume":"38","author":"Smadja","year":"2003","journal-title":"Genes Chromosomes Cancer"},{"issue":"4","key":"10.1016\/j.hoc.2007.08.004_bib38","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood.V100.4.1417.h81602001417_1417_1424","article-title":"Genomic abnormalities in monoclonal gammopathy of undetermined significance","volume":"100","author":"Fonseca","year":"2002","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.hoc.2007.08.004_bib39","first-page":"4546","article-title":"14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du Myelome","volume":"59","author":"Avet-Loiseau","year":"1999","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.hoc.2007.08.004_bib40","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1038\/sj.leu.2403518","article-title":"Both IGH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma","volume":"18","author":"Kaufmann","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2007.08.004_bib41","doi-asserted-by":"crossref","DOI":"10.2202\/1544-6115.1018","article-title":"Evaluation of multiple models to distinguish closely related forms of disease using DNA microarray data: an application to multiple myeloma","volume":"3","author":"Hardin","year":"2004","journal-title":"Stat Appl Genet Mol Biol"},{"issue":"5","key":"10.1016\/j.hoc.2007.08.004_bib42","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1182\/blood.V99.5.1745","article-title":"Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells","volume":"99","author":"Zhan","year":"2002","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2007.08.004_bib43","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1182\/blood-2006-07-037077","article-title":"Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis","volume":"109","author":"Zhan","year":"2007","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2007.08.004_bib44","first-page":"1659","article-title":"Oncogenes in multiple myeloma: point mutation of N-ras","volume":"5","author":"Paquette","year":"1990","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.hoc.2007.08.004_bib45","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1084\/jem.170.5.1715","article-title":"Ras oncogene mutation in multiple myeloma","volume":"170","author":"Neri","year":"1989","journal-title":"J Exp Med"},{"issue":"3","key":"10.1016\/j.hoc.2007.08.004_bib46","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/humu.1177","article-title":"High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis","volume":"18","author":"Bezieau","year":"2001","journal-title":"Hum Mutat"},{"issue":"7","key":"10.1016\/j.hoc.2007.08.004_bib47","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1182\/blood.V88.7.2699.bloodjournal8872699","article-title":"Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial","volume":"88","author":"Liu","year":"1996","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2007.08.004_bib48","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1182\/blood.V81.10.2708.2708","article-title":"Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias","volume":"81","author":"Corradini","year":"1993","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2007.08.004_bib49","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1182\/blood-2004-03-0833","article-title":"Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors","volume":"105","author":"Rasmussen","year":"2005","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2007.08.004_bib50","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1182\/blood.V99.6.2185","article-title":"Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation","volume":"99","author":"Avet-Loiseau","year":"2002","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2007.08.004_bib51","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1182\/blood-2002-06-1675","article-title":"In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression","volume":"101","author":"Keats","year":"2003","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.hoc.2007.08.004_bib52","first-page":"4058","article-title":"Detection of t(4;14)(p16.3;q32) chromosomal translocation in multiple myeloma by reverse transcription-polymerase chain reaction analysis of IGH-MMSET fusion transcripts","volume":"60","author":"Malgeri","year":"2000","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.hoc.2007.08.004_bib53","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1365-2141.2006.06467.x","article-title":"Upregulation of translational machinery and distinct genetic subgroups characterise hyperdiploidy in multiple myeloma","volume":"136","author":"Agnelli","year":"2007","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.hoc.2007.08.004_bib54","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1158\/0008-5472.CAN-06-4046","article-title":"Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling","volume":"67","author":"Chng","year":"2007","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.hoc.2007.08.004_bib55","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1046\/j.1365-2141.2002.03757.x","article-title":"Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma","volume":"118","author":"Fassas","year":"2002","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.hoc.2007.08.004_bib56","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1046\/j.1365-2141.1997.2443061.x","article-title":"Hypodiploidy and 22q11 rearrangements at diagnosis are associated with poor prognosis in patients with multiple myeloma","volume":"98","author":"Calasanz","year":"1997","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.hoc.2007.08.004_bib57","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/sj.leu.2404172","article-title":"Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations","volume":"20","author":"Chng","year":"2006","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.hoc.2007.08.004_bib58","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/gcc.20375","article-title":"Analysis of genetic abnormalities provides insights into genetic evolution of hyperdiploid myeloma","volume":"45","author":"Chng","year":"2006","journal-title":"Genes Chromosomes Cancer"},{"issue":"10","key":"10.1016\/j.hoc.2007.08.004_bib59","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1093\/carcin\/13.10.1681","article-title":"Plasmacytomagenesis in mice: model of neoplastic development dependent upon chromosomal translocations","volume":"13","author":"Potter","year":"1992","journal-title":"Carcinogenesis"},{"issue":"10","key":"10.1016\/j.hoc.2007.08.004_bib60","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1182\/blood.V99.10.3735","article-title":"Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients","volume":"99","author":"Fonseca","year":"2002","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.hoc.2007.08.004_bib61","first-page":"5640","article-title":"High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies","volume":"58","author":"Avet-Loiseau","year":"1998","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.hoc.2007.08.004_bib62","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1080\/10428190600822128","article-title":"Ten years and counting: so what do we know about t(4;14)(p16;q32) multiple myeloma","volume":"47","author":"Keats","year":"2006","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"10.1016\/j.hoc.2007.08.004_bib63","doi-asserted-by":"crossref","first-page":"4060","DOI":"10.1182\/blood-2004-09-3704","article-title":"Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients","volume":"105","author":"Keats","year":"2005","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2007.08.004_bib64","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1182\/blood-2002-09-2801","article-title":"A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH\/MMSET fusion transcript","volume":"101","author":"Santra","year":"2003","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2007.08.004_bib65","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1365-2141.2004.04996.x","article-title":"Correlation of TACC3, FGFR3, MMSET and p21 expression with the t(4;14)(p16.3;q32) in multiple myeloma","volume":"126","author":"Stewart","year":"2004","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.hoc.2007.08.004_bib66","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/j.1365-2141.2005.05664.x","article-title":"Identification of ID-1 as a potential target gene of MMSET in multiple myeloma","volume":"130","author":"Hudlebusch","year":"2005","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.hoc.2007.08.004_bib67","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1182\/blood.V95.3.992.003k29_992_998","article-title":"Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis","volume":"95","author":"Plowright","year":"2000","journal-title":"Blood"},{"issue":"27","key":"10.1016\/j.hoc.2007.08.004_bib68","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1038\/sj.onc.1204465","article-title":"Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations","volume":"20","author":"Ronchetti","year":"2001","journal-title":"Oncogene"},{"issue":"8","key":"10.1016\/j.hoc.2007.08.004_bib69","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1182\/blood.V97.8.2413","article-title":"The myeloma-associated oncogene fibroblast growth factor receptor 3 is transforming in hematopoietic cells","volume":"97","author":"Li","year":"2001","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2007.08.004_bib70","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/sj.leu.2403347","article-title":"Targeting FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD173074","volume":"18","author":"Grand","year":"2004","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.hoc.2007.08.004_bib71","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1182\/blood-2003-10-3650","article-title":"Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma","volume":"103","author":"Trudel","year":"2004","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.hoc.2007.08.004_bib72","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1182\/blood-2004-10-3913","article-title":"CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma","volume":"105","author":"Trudel","year":"2005","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2007.08.004_bib73","doi-asserted-by":"crossref","first-page":"4039","DOI":"10.1182\/blood-2005-10-4179","article-title":"The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells","volume":"107","author":"Trudel","year":"2006","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2007.08.004_bib74","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.1365-2141.2005.05741.x","article-title":"Transcription repression activity is associated with the type I isoform of the MMSET gene involved in t(4;14) in multiple myeloma","volume":"131","author":"Todoerti","year":"2005","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.hoc.2007.08.004_bib75","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1182\/blood.V99.10.3857","article-title":"NUP98 is fused to the NSD3 gene in acute myeloid leukemia associated with t(8;11)(p11.2;p15)","volume":"99","author":"Rosati","year":"2002","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2007.08.004_bib76","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1006\/geno.2001.6524","article-title":"NSD3, a new SET domain-containing gene, maps to 8p12 and is amplified in human breast cancer cell lines","volume":"74","author":"Angrand","year":"2001","journal-title":"Genomics"},{"issue":"27","key":"10.1016\/j.hoc.2007.08.004_bib77","doi-asserted-by":"crossref","first-page":"9625","DOI":"10.1073\/pnas.0504126102","article-title":"High-resolution genomic profiles of human lung cancer","volume":"102","author":"Tonon","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.hoc.2007.08.004_bib78","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1182\/blood.V98.4.1264","article-title":"A novel gene, NSD1, is fused to NUP98 in the t(5;11)(q35;p15.5) in de novo childhood acute myeloid leukemia","volume":"98","author":"Jaju","year":"2001","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2007.08.004_bib79","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1182\/blood-2002-10-3017","article-title":"Clinical and biologic implications of recurrent genomic aberrations in myeloma","volume":"101","author":"Fonseca","year":"2003","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.hoc.2007.08.004_bib80","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1182\/blood-2006-08-040410","article-title":"Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome","volume":"109","author":"Avet-Loiseau","year":"2007","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2007.08.004_bib81","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1365-2141.2004.04867.x","article-title":"The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant","volume":"125","author":"Chang","year":"2004","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.hoc.2007.08.004_bib82","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1046\/j.1365-2141.2003.03983_5.x","article-title":"t(4;14)(p16.3;q32) is strongly associated with a shorter survival in myeloma patients","volume":"120","author":"Winkler","year":"2003","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.hoc.2007.08.004_bib83","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1182\/blood-2002-03-0749","article-title":"Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy","volume":"100","author":"Moreau","year":"2002","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2007.08.004_bib84","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1080\/1042819031000111035","article-title":"C-MAF oncogene dysregulation in multiple myeloma: frequency and biological relevance","volume":"44","author":"Rasmussen","year":"2003","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.hoc.2007.08.004_bib85","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S1535-6108(04)00019-4","article-title":"Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma","volume":"5","author":"Hurt","year":"2004","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.hoc.2007.08.004_bib86","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/gcc.20404","article-title":"Molecular characterization of human multiple myeloma cell lines by integrative genomics: insights into the biology of the disease","volume":"46","author":"Lombardi","year":"2007","journal-title":"Genes Chromosomes Cancer"},{"issue":"46","key":"10.1016\/j.hoc.2007.08.004_bib87","doi-asserted-by":"crossref","first-page":"6936","DOI":"10.1038\/sj.onc.1208844","article-title":"ARK5 is transcriptionally regulated by the Large-MAF family and mediates IGF-1-induced cell invasion in multiple myeloma: ARK5 as a new molecular determinant of malignant multiple myeloma","volume":"24","author":"Suzuki","year":"2005","journal-title":"Oncogene"},{"issue":"26","key":"10.1016\/j.hoc.2007.08.004_bib88","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1056\/NEJMoa030847","article-title":"The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma","volume":"349","author":"Tian","year":"2003","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.hoc.2007.08.004_bib89","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/hon.803","article-title":"Osteopontin dysregulation and lytic bone lesions in multiple myeloma","volume":"25","author":"Robbiani","year":"2007","journal-title":"Hematol Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2007.08.004_bib90","doi-asserted-by":"crossref","first-page":"795","DOI":"10.3324\/haematol.11052","article-title":"Multiple myeloma primary cells show a highly rearranged unbalanced genome with amplifications and homozygous deletions irrespective of the presence of immunoglobulin-related chromosome translocations","volume":"92","author":"Largo","year":"2007","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.hoc.2007.08.004_bib91","first-page":"184","article-title":"Identification of overexpressed genes in frequently gained\/amplified chromosome regions in multiple myeloma","volume":"91","author":"Largo","year":"2006","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.hoc.2007.08.004_bib92","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1182\/blood-2006-02-005496","article-title":"Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma","volume":"108","author":"Walker","year":"2006","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2007.08.004_bib93","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrc1802","article-title":"Common markers of proliferation","volume":"6","author":"Whitfield","year":"2006","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"10.1016\/j.hoc.2007.08.004_bib94","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1182\/blood-2006-09-044974","article-title":"Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib","volume":"109","author":"Mulligan","year":"2007","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2007.08.004_bib95","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/(SICI)1098-2264(199706)19:2<124::AID-GCC8>3.0.CO;2-0","article-title":"Molecular cytogenetic abnormalities in multiple myeloma and plasma cell leukemia measured using comparative genomic hybridization","volume":"19","author":"Avet-Loiseau","year":"1997","journal-title":"Genes Chromosomes Cancer"},{"issue":"5","key":"10.1016\/j.hoc.2007.08.004_bib96","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1182\/blood.V91.5.1732","article-title":"Jumping translocations of chromosome 1q in multiple myeloma: evidence for a mechanism involving decondensation of pericentromeric heterochromatin","volume":"91","author":"Sawyer","year":"1998","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2007.08.004_bib97","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1182\/blood-2004-04-1319","article-title":"Prognostic and biologic significance of chromosomal imbalances assessed by comparative genomic hybridization in multiple myeloma","volume":"104","author":"Gutierrez","year":"2004","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2007.08.004_bib98","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/gcc.20231","article-title":"Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics","volume":"44","author":"Cremer","year":"2005","journal-title":"Genes Chromosomes Cancer"},{"issue":"11","key":"10.1016\/j.hoc.2007.08.004_bib99","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1038\/sj.leu.2404403","article-title":"Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma","volume":"20","author":"Fonseca","year":"2006","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.hoc.2007.08.004_bib100","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1365-2141.2006.06325.x","article-title":"Multiple myeloma patients with CKS1B gene amplification have a shorter progression-free survival post-autologous stem cell transplantation","volume":"135","author":"Chang","year":"2006","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.hoc.2007.08.004_bib101","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/gcc.1189","article-title":"Novel evidence of a role for chromosome 1 pericentric heterochromatin in the pathogenesis of B-cell lymphoma and multiple myeloma","volume":"32","author":"Le Baccon","year":"2001","journal-title":"Genes Chromosomes Cancer"},{"issue":"1","key":"10.1016\/j.hoc.2007.08.004_bib102","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/gcc.20109","article-title":"Genomic instability in multiple myeloma: evidence for jumping segmental duplications of chromosome arm 1q","volume":"42","author":"Sawyer","year":"2005","journal-title":"Genes Chromosomes Cancer"},{"issue":"6","key":"10.1016\/j.hoc.2007.08.004_bib103","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/j.1365-2141.2006.06237.x","article-title":"Significant increase of CKS1B amplification from monoclonal gammopathy of undetermined significance to multiple myeloma and plasma cell leukaemia as demonstrated by interphase fluorescence in situ hybridisation","volume":"134","author":"Chang","year":"2006","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.hoc.2007.08.004_bib104","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.1365-2141.2006.06481.x","article-title":"Abnormalities of chromosome 1p\/q are highly associated with chromosome 13\/13q deletions and are an adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma","volume":"136","author":"Wu","year":"2007","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.hoc.2007.08.004_bib105","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1182\/blood-2006-07-038430","article-title":"A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1","volume":"109","author":"Shaughnessy","year":"2007","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2007.08.004_bib106","doi-asserted-by":"crossref","first-page":"4995","DOI":"10.1182\/blood-2006-07-038703","article-title":"CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms","volume":"109","author":"Zhan","year":"2007","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2007.08.004_bib107","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1182\/blood.V86.11.4250.bloodjournal86114250","article-title":"Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities","volume":"86","author":"Tricot","year":"1995","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2007.08.004_bib108","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1111\/j.1365-2141.2000.02488.x","article-title":"Chromosome 13 abnormalities in multiple myeloma are mostly monosomy 13","volume":"111","author":"Avet-Louseau","year":"2000","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.hoc.2007.08.004_bib109","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/sj.leu.2402125","article-title":"Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy","volume":"15","author":"Fonseca","year":"2001","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.hoc.2007.08.004_bib110","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1182\/blood.V96.4.1505","article-title":"High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH","volume":"96","author":"Shaughnessy","year":"2000","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2007.08.004_bib111","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1182\/blood.V97.6.1566","article-title":"Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy","volume":"97","author":"Facon","year":"2001","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2007.08.004_bib112","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1182\/blood.V95.6.1925","article-title":"Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization","volume":"95","author":"Zojer","year":"2000","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2007.08.004_bib113","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1038\/sj.leu.2401909","article-title":"Deletions of chromosome 13q in monoclonal gammopathy of undetermined significance","volume":"14","author":"Konigsberg","year":"2000","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.hoc.2007.08.004_bib114","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1182\/blood.V98.4.1271","article-title":"The t(4;14)(p16.3;q32) is strongly associated with chromosome 13 abnormalities in both multiple myeloma and monoclonal gammopathy of undetermined significance","volume":"98","author":"Fonseca","year":"2001","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2007.08.004_bib115","doi-asserted-by":"crossref","first-page":"4116","DOI":"10.1182\/blood.V99.11.4116","article-title":"Down-regulation of candidate tumor suppressor genes within chromosome band 13q14.3 is independent of the DNA methylation pattern in B-cell chronic lymphocytic leukemia","volume":"99","author":"Mertens","year":"2002","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2007.08.004_bib116","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/gcc.10140","article-title":"Delineation of the minimal region of loss at 13q14 in multiple myeloma","volume":"36","author":"Elnenaei","year":"2003","journal-title":"Genes Chromosomes Cancer"},{"issue":"12","key":"10.1016\/j.hoc.2007.08.004_bib117","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.1182\/blood.V95.12.4008","article-title":"Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities","volume":"95","author":"Desikan","year":"2000","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2007.08.004_bib118","first-page":"715","article-title":"Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an eastern cooperative oncology group study","volume":"62","author":"Fonseca","year":"2002","journal-title":"Cancer Res"},{"issue":"10","key":"10.1016\/j.hoc.2007.08.004_bib119","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.1182\/blood-2002-09-2873","article-title":"Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with total therapy I: interpretation in the context of global gene expression","volume":"101","author":"Shaughnessy","year":"2003","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2007.08.004_bib120","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/sj.leu.2404413","volume":"21","author":"Gutierrez","year":"2007","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.hoc.2007.08.004_bib121","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.cancergencyto.2004.01.005","article-title":"Evidence for gains at 15q and 20q in brain metastases of prostate cancer","volume":"154","author":"Wullich","year":"2004","journal-title":"Cancer Genet Cytogenet"},{"issue":"54","key":"10.1016\/j.hoc.2007.08.004_bib122","first-page":"1857","article-title":"Chromosome arm 20q gains and other genomic alterations in esophageal squamous cell carcinoma, as analyzed by comparative genomic hybridization and fluorescence in situ hybridization","volume":"50","author":"Fujita","year":"2003","journal-title":"Hepatogastroenterology"},{"issue":"6","key":"10.1016\/j.hoc.2007.08.004_bib123","first-page":"4141","article-title":"Cytogenetic data as a prognostic factor in multiple myeloma patients: involvement of 1p12 region an adverse prognostic factor","volume":"24","author":"Panani","year":"2004","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1016\/j.hoc.2007.08.004_bib124","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1182\/blood.V81.1.128.128","article-title":"p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy","volume":"81","author":"Neri","year":"1993","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2007.08.004_bib125","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/j.1365-2141.1992.tb08253.x","article-title":"Rare occurrence of P53 gene mutations in multiple myeloma","volume":"81","author":"Preudhomme","year":"1992","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.hoc.2007.08.004_bib126","first-page":"2539","article-title":"p53 and RAS gene mutations in multiple myeloma","volume":"7","author":"Portier","year":"1992","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.hoc.2007.08.004_bib127","first-page":"758","article-title":"Inactivation of tumor suppressor genes, p53 and Rb1, in plasma cell dyscrasias","volume":"8","author":"Corradini","year":"1994","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.hoc.2007.08.004_bib128","first-page":"1015","article-title":"Mutations of the p53 gene in human myeloma cell lines","volume":"7","author":"Mazars","year":"1992","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.hoc.2007.08.004_bib129","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/sj.leu.2404524","article-title":"Clinical significance of TP53 mutation in myeloma","volume":"21","author":"Chng","year":"2007","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.hoc.2007.08.004_bib130","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1046\/j.1365-2141.1999.01615.x","article-title":"P53 deletion is not a frequent event in multiple myeloma","volume":"106","author":"Avet-Loiseau","year":"1999","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.hoc.2007.08.004_bib131","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1182\/blood-2004-04-1363","article-title":"p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation","volume":"105","author":"Chang","year":"2005","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.hoc.2007.08.004_bib132","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1182\/blood-2005-04-1411","article-title":"Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy","volume":"106","author":"Gertz","year":"2005","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2007.08.004_bib133","first-page":"1091","article-title":"Expression of C-myc p62 oncoprotein in multiple myeloma: an immunohistochemical study of 180 cases","volume":"13","author":"Skopelitou","year":"1993","journal-title":"Anticancer Res"},{"issue":"17","key":"10.1016\/j.hoc.2007.08.004_bib134","first-page":"4701","article-title":"Altered expression of growth-regulated protooncogenes in human malignant plasma cells","volume":"49","author":"Palumbo","year":"1989","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.hoc.2007.08.004_bib135","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood.V71.1.30.30","article-title":"Alteration and abnormal expression of the c-myc oncogene in human multiple myeloma","volume":"71","author":"Selvanayagam","year":"1988","journal-title":"Blood"},{"issue":"5\u20136","key":"10.1016\/j.hoc.2007.08.004_bib136","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3109\/10428199709039043","article-title":"Disease progression in patients with multiple myeloma is associated with a concurrent alteration in the expression of both oncogenes and tumour suppressor genes and can be monitored by the oncoprotein phenotype","volume":"25","author":"Pope","year":"1997","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.hoc.2007.08.004_bib137","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/gcc.10211","article-title":"Heterogeneous pattern of chromosomal breakpoints involving the MYC locus in multiple myeloma","volume":"37","author":"Fabris","year":"2003","journal-title":"Genes Chromosomes Cancer"},{"issue":"1","key":"10.1016\/j.hoc.2007.08.004_bib138","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1073\/pnas.97.1.228","article-title":"Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma","volume":"97","author":"Shou","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.hoc.2007.08.004_bib139","first-page":"124","article-title":"Complex translocation disrupts c-myc regulation in a human plasma cell myeloma","volume":"8","author":"Hollis","year":"1988","journal-title":"Mol Cell Biol"},{"issue":"10","key":"10.1016\/j.hoc.2007.08.004_bib140","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1182\/blood.V98.10.3082","article-title":"Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors","volume":"98","author":"Avet-Loiseau","year":"2001","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2007.08.004_bib141","first-page":"529","article-title":"Gene abnormalities in multiple myeloma; the relevance of TP53, MDM2, and CDKN2A","volume":"88","author":"Elnenaei","year":"2003","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.hoc.2007.08.004_bib142","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1182\/blood.V89.7.2500","article-title":"Frequent hypermethylation of p16 and p15 genes in multiple myeloma","volume":"89","author":"Ng","year":"1997","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2007.08.004_bib143","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1182\/blood-2006-05-024661","article-title":"Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications","volume":"109","author":"Gonzalez-Paz","year":"2007","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2007.08.004_bib144","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1182\/blood-2006-09-049510","article-title":"Methylation and expression of the p16INK4A tumor suppressor gene in multiple myeloma","volume":"109","author":"Dib","year":"2007","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2007.08.004_bib145","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.canlet.2004.09.038","article-title":"p16 gene methylation lacks correlation with angiogenesis and prognosis in multiple myeloma","volume":"222","author":"Ribas","year":"2005","journal-title":"Cancer Lett"},{"issue":"9","key":"10.1016\/j.hoc.2007.08.004_bib146","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1038\/sj.leu.2402609","article-title":"Alterations of the cyclin D1\/pRb\/p16(INK4A) pathway in multiple myeloma","volume":"16","author":"Kramer","year":"2002","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.hoc.2007.08.004_bib147","first-page":"1551","article-title":"The association of increased p14ARF\/p16INK4a and p15INK4a gene expression with proliferative activity and the clinical course of multiple myeloma","volume":"91","author":"Sarasquete","year":"2006","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.hoc.2007.08.004_bib148","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1046\/j.1365-2141.2002.03749.x","article-title":"Methylation is an inactivating mechanism of the p16 gene in multiple myeloma associated with high plasma cell proliferation and short survival","volume":"118","author":"Mateos","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2007.08.004_bib149","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1747-1028-1-23","article-title":"Paradoxical expression of INK4c in proliferative multiple myeloma tumors: bi-allelic deletion vs increased expression","volume":"1","author":"Dib","year":"2006","journal-title":"Cell Div"},{"issue":"1","key":"10.1016\/j.hoc.2007.08.004_bib150","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1046\/j.1365-2141.1997.8552482.x","article-title":"Analysis of the p16INK4A, p15INK4B and p18INK4C genes in multiple myeloma","volume":"96","author":"Tasaka","year":"1997","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.hoc.2007.08.004_bib151","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1182\/blood-2003-09-3064","article-title":"Characterization of clonogenic multiple myeloma cells","volume":"103","author":"Matsui","year":"2004","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2007.08.004_bib152","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1073\/pnas.0611682104","article-title":"Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma","volume":"104","author":"Peacock","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.hoc.2007.08.004_bib153","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/nrc1592","article-title":"Leukaemia stem cells and the evolution of cancer-stem-cell research","volume":"5","author":"Huntly","year":"2005","journal-title":"Nat Rev Cancer"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858807001128?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858807001128?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:53:01Z","timestamp":1760183581000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858807001128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12]]},"references-count":153,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["S0889858807001128"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2007.08.004","relation":{},"ISSN":["0889-8588"],"issn-type":[{"type":"print","value":"0889-8588"}],"subject":[],"published":{"date-parts":[[2007,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular Pathogenesis of Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2007.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}